Vericel (VCEL) Misses Q1 EPS by 1c, Revenues Miss; Raises FY19 Total MACI and Epicel Sales Outlook

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/5/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. FIS
6. DUOL
7. ARM
8. SWKS
9. SPY
10. XYZ

Go back to Vericel (VCEL) Misses Q1 EPS by 1c, Revenues Miss; Raises FY19 Total MACI and Epicel Sales Outlook

Vericel Reports First Quarter 2019 Financial Results and Raises Full Year 2019 Revenue Guidance

May 7, 2019 7:02 AM EDT

MACI Revenue Increased 38% Over First Quarter 2018

Positive Cash Flow in First Quarter

Announced Exclusive License Agreement with MediWound for North American Rights to NexoBrid

Conference Call Today at 8:00am Eastern Time

CAMBRIDGE, Mass., May 07, 2019 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ: VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today reported financial results for the first quarter ended March 31, 2019, and recent business highlights.

First... More